Page 12 - Executive Albert Bourla News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer Inc on Tuesday forecast $26 billion in COVID-19 vaccine sales this year, a more than 70% jump from its last projection, reflecting new contracts with governments around the world trying to halt the pandemic through rapid vaccination. The raised goal assumes 1.6 billion doses of vaccine, which is co-developed with BioNTech SE, will be delivered in the year, with the two-shot vaccine emerging as the best-selling product for the U.S. drugmaker in the first quarter. It is expected to make up for more than one-third of Pfizer's full-year sales, with the company in supply talks with severa...

Published May 4, 2021 10:00pm Pfizer sharply increased its projections for 2021 revenues and profits on Tuesday, citing much higher COVID-19 vaccine sales as it targets the inoculations as a "durable" revenue stream. The drugmaker, which has a number of projects to expand vaccinations to additional populations and to provide booster doses, now estimates 2021 revenues of $26 billion from the vaccine, up from $15 billion previously. Pfizer now sees profits of between $3.55 and $3.65 a share for the year, an increase of 45 cents from the previous estimate. Chief Executive Albert Bourla exp...